Roche Flu Drug Xofluza Cleared for Generic Production Under Pandemic-Prep Deal
- The Medicines Patent Pool signed sub-licensing deals with 11 generic manufacturers to produce Roche's flu antiviral Xofluza (baloxavir marboxil).
- The agreements, building on MPP's broader license with Roche, cover supply to roughly 129 low- and middle-income countries and include technical support for regulatory approval.
- They also carry pandemic-specific provisions meant to ease supply, territory and royalty constraints if a global flu outbreak occurs.
💡 Points
Roche is front-running compulsory-licensing pressure here, not waiting for a pandemic to force its hand the way COVID access fights forced others — cheap reputational insurance bought years early. But 11 sub-licensees on paper isn't surge capacity: without tech-transfer and validation runs now, that capacity stays theoretical until an outbreak tests it. Still, MPP's Xofluza network beats what Gilead ever built for oseltamivir — a real bar-raise on pandemic-prep licensing.
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic ↗